KR20160150113A - 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 - Google Patents
연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 Download PDFInfo
- Publication number
- KR20160150113A KR20160150113A KR1020167035558A KR20167035558A KR20160150113A KR 20160150113 A KR20160150113 A KR 20160150113A KR 1020167035558 A KR1020167035558 A KR 1020167035558A KR 20167035558 A KR20167035558 A KR 20167035558A KR 20160150113 A KR20160150113 A KR 20160150113A
- Authority
- KR
- South Korea
- Prior art keywords
- bleeding
- days
- cycle
- extended
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003433 contraceptive agent Substances 0.000 title claims abstract description 12
- 206010027514 Metrorrhagia Diseases 0.000 title description 5
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 23
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 23
- 229960002568 ethinylestradiol Drugs 0.000 claims description 23
- 239000000583 progesterone congener Substances 0.000 claims description 22
- 229940011871 estrogen Drugs 0.000 claims description 18
- 239000000262 estrogen Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 15
- 229940088597 hormone Drugs 0.000 claims description 14
- 239000005556 hormone Substances 0.000 claims description 14
- 230000002254 contraceptive effect Effects 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 68
- 230000002035 prolonged effect Effects 0.000 abstract description 6
- 230000003054 hormonal effect Effects 0.000 abstract description 5
- 229940124558 contraceptive agent Drugs 0.000 abstract description 4
- 208000032843 Hemorrhage Diseases 0.000 description 76
- 208000034158 bleeding Diseases 0.000 description 67
- 239000006187 pill Substances 0.000 description 23
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- 229960004400 levonorgestrel Drugs 0.000 description 12
- 230000002175 menstrual effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 206010036618 Premenstrual syndrome Diseases 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 206010034754 petechiae Diseases 0.000 description 8
- 208000037093 Menstruation Disturbances Diseases 0.000 description 7
- 231100000544 menstrual irregularity Toxicity 0.000 description 7
- 230000005906 menstruation Effects 0.000 description 7
- 239000003539 oral contraceptive agent Substances 0.000 description 7
- 206010037549 Purpura Diseases 0.000 description 6
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 6
- 229960004845 drospirenone Drugs 0.000 description 6
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 6
- 229940127234 oral contraceptive Drugs 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 201000009273 Endometriosis Diseases 0.000 description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010036049 Polycystic ovaries Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 206010061592 cardiac fibrillation Diseases 0.000 description 4
- 230000002600 fibrillogenic effect Effects 0.000 description 4
- 208000007106 menorrhagia Diseases 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 3
- 229960004976 desogestrel Drugs 0.000 description 3
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 3
- 229960003309 dienogest Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 229960000417 norgestimate Drugs 0.000 description 3
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 208000035432 Unintended pregnancy Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- -1 e. G. Substances 0.000 description 2
- 239000003687 estradiol congener Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960002941 etonogestrel Drugs 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229940124566 female contraceptive agent Drugs 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56644304P | 2004-04-30 | 2004-04-30 | |
| US60/566,443 | 2004-04-30 | ||
| US57502404P | 2004-05-28 | 2004-05-28 | |
| US60/575,024 | 2004-05-28 | ||
| US57719904P | 2004-06-07 | 2004-06-07 | |
| US60/577,199 | 2004-06-07 | ||
| US63838004P | 2004-12-27 | 2004-12-27 | |
| US60/638,380 | 2004-12-27 | ||
| US66006805P | 2005-03-10 | 2005-03-10 | |
| US60/660,068 | 2005-03-10 | ||
| PCT/EP2005/004777 WO2005105103A2 (en) | 2004-04-30 | 2005-04-29 | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157012286A Division KR101812160B1 (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160150113A true KR20160150113A (ko) | 2016-12-28 |
Family
ID=35056905
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167035558A Ceased KR20160150113A (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
| KR1020157012286A Expired - Lifetime KR101812160B1 (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
| KR1020137001481A Ceased KR20130022425A (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
| KR1020067022523A Ceased KR20070004919A (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157012286A Expired - Lifetime KR101812160B1 (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
| KR1020137001481A Ceased KR20130022425A (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
| KR1020067022523A Ceased KR20070004919A (ko) | 2004-04-30 | 2005-04-29 | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8163721B2 (enExample) |
| EP (1) | EP1747001B1 (enExample) |
| JP (4) | JP2007535519A (enExample) |
| KR (4) | KR20160150113A (enExample) |
| CN (1) | CN103127156A (enExample) |
| AR (1) | AR048722A1 (enExample) |
| AU (1) | AU2005237255B2 (enExample) |
| BR (1) | BRPI0510493A (enExample) |
| CA (1) | CA2562296A1 (enExample) |
| CR (1) | CR8709A (enExample) |
| DK (1) | DK1747001T3 (enExample) |
| EA (2) | EA016625B1 (enExample) |
| EC (1) | ECSP066999A (enExample) |
| ES (1) | ES2704999T3 (enExample) |
| HU (1) | HUE041475T2 (enExample) |
| IL (1) | IL178458A (enExample) |
| LT (1) | LT1747001T (enExample) |
| MX (1) | MXPA06012567A (enExample) |
| MY (1) | MY151322A (enExample) |
| NO (1) | NO341685B1 (enExample) |
| NZ (1) | NZ586107A (enExample) |
| PA (1) | PA8631801A1 (enExample) |
| PE (1) | PE20060467A1 (enExample) |
| SG (2) | SG10201701904TA (enExample) |
| SI (1) | SI1747001T1 (enExample) |
| SV (1) | SV2006002100A (enExample) |
| TW (1) | TWI374735B (enExample) |
| UY (1) | UY28875A1 (enExample) |
| WO (1) | WO2005105103A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| US20070088010A1 (en) * | 2005-10-17 | 2007-04-19 | Doris Huebler | Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest |
| EP1977752A1 (de) * | 2007-03-01 | 2008-10-08 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
| DE102007011105A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| CA2736707A1 (en) * | 2008-09-16 | 2010-03-25 | Playtex Products, Llc | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same |
| US9198919B2 (en) | 2008-10-08 | 2015-12-01 | Agile Therapeutics, Inc. | Contraceptive transdermal delivery of hormones |
| CA2740002C (en) | 2008-10-08 | 2016-11-01 | Agile Therapeutics, Inc. | Transdermal delivery |
| CA2740004A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| CA2756222A1 (en) | 2009-03-27 | 2010-09-30 | Agile Therapeutics, Inc. | Transdermal delivery |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
| MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| PL3106148T3 (pl) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
| EP3310333B1 (en) | 2015-06-18 | 2020-04-29 | Estetra SPRL | Orodispersible dosage unit containing an estetrol component |
| SI3313408T1 (sl) * | 2015-06-23 | 2024-04-30 | Laboratorios Leon Farma Sa | Kontraceptiv na osnovi drospirenona za pacientko s prekomerno težo |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| US12138270B2 (en) | 2021-09-07 | 2024-11-12 | Millicent Pharma Limited | Contraceptive regimen including reduced level of estrogen |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244096A (en) | 1988-04-22 | 1993-09-14 | Stoner Fred L | Preventive treatment kit against sexually transmitted disease |
| WO1993013801A1 (en) | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Treatment for atherosclerosis |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| US5552394A (en) | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
| IL127797A (en) | 1996-07-26 | 2004-08-31 | Wyeth Corp | A one-step method of contraception and a kit containing a combination of progestin and estrogen |
| US6451778B1 (en) * | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
| US5842441A (en) | 1996-08-26 | 1998-12-01 | Pharmalett Denmark A/S | Medicated and individualized treatment shampoo for dermatological disturbances of companion animals |
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| DE122009000007I2 (de) | 1999-08-31 | 2011-07-21 | Bayer Schering Pharma | Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel. |
| CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| US6653298B2 (en) * | 2000-01-14 | 2003-11-25 | Sterix Limited | Composition |
| DE10045380A1 (de) * | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
| IL145876A0 (en) | 2000-10-17 | 2002-07-25 | Pfizer Prod Inc | Methods and kits for improving vascular health |
| US20020193356A1 (en) * | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
| US20030018018A1 (en) | 2001-07-10 | 2003-01-23 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| US8501720B2 (en) | 2004-07-30 | 2013-08-06 | Bayer Pharma AG | Method for treatment of dysmenorrhea |
-
2005
- 2005-04-19 MY MYPI20051728 patent/MY151322A/en unknown
- 2005-04-27 UY UY28875A patent/UY28875A1/es not_active IP Right Cessation
- 2005-04-29 TW TW094113795A patent/TWI374735B/zh not_active IP Right Cessation
- 2005-04-29 CA CA002562296A patent/CA2562296A1/en not_active Abandoned
- 2005-04-29 SG SG10201701904TA patent/SG10201701904TA/en unknown
- 2005-04-29 KR KR1020167035558A patent/KR20160150113A/ko not_active Ceased
- 2005-04-29 HU HUE05740127A patent/HUE041475T2/hu unknown
- 2005-04-29 ES ES05740127T patent/ES2704999T3/es not_active Expired - Lifetime
- 2005-04-29 KR KR1020157012286A patent/KR101812160B1/ko not_active Expired - Lifetime
- 2005-04-29 CN CN2012105794658A patent/CN103127156A/zh active Pending
- 2005-04-29 SV SV2005002100A patent/SV2006002100A/es unknown
- 2005-04-29 EA EA200601908A patent/EA016625B1/ru not_active IP Right Cessation
- 2005-04-29 EA EA201200377A patent/EA031227B1/ru not_active IP Right Cessation
- 2005-04-29 KR KR1020137001481A patent/KR20130022425A/ko not_active Ceased
- 2005-04-29 KR KR1020067022523A patent/KR20070004919A/ko not_active Ceased
- 2005-04-29 NZ NZ586107A patent/NZ586107A/en not_active IP Right Cessation
- 2005-04-29 JP JP2007509994A patent/JP2007535519A/ja not_active Withdrawn
- 2005-04-29 MX MXPA06012567A patent/MXPA06012567A/es active IP Right Grant
- 2005-04-29 SI SI200532240T patent/SI1747001T1/sl unknown
- 2005-04-29 BR BRPI0510493-9A patent/BRPI0510493A/pt not_active Application Discontinuation
- 2005-04-29 EP EP05740127.5A patent/EP1747001B1/en not_active Revoked
- 2005-04-29 DK DK05740127.5T patent/DK1747001T3/en active
- 2005-04-29 LT LTEP05740127.5T patent/LT1747001T/lt unknown
- 2005-04-29 AU AU2005237255A patent/AU2005237255B2/en not_active Expired
- 2005-04-29 WO PCT/EP2005/004777 patent/WO2005105103A2/en not_active Ceased
- 2005-04-29 SG SG200902990-1A patent/SG152288A1/en unknown
- 2005-05-02 AR ARP050101738A patent/AR048722A1/es not_active Application Discontinuation
- 2005-05-02 US US11/118,779 patent/US8163721B2/en not_active Expired - Fee Related
- 2005-05-03 PE PE2005000490A patent/PE20060467A1/es not_active Application Discontinuation
- 2005-05-03 PA PA20058631801A patent/PA8631801A1/es unknown
-
2006
- 2006-10-05 IL IL178458A patent/IL178458A/en active IP Right Grant
- 2006-10-25 CR CR8709A patent/CR8709A/es not_active Application Discontinuation
- 2006-11-13 EC EC2006006999A patent/ECSP066999A/es unknown
- 2006-11-28 NO NO20065499A patent/NO341685B1/no unknown
-
2012
- 2012-04-17 US US13/448,585 patent/US20120202779A1/en not_active Abandoned
- 2012-10-12 JP JP2012227416A patent/JP6134491B2/ja not_active Expired - Lifetime
-
2015
- 2015-03-09 US US14/642,096 patent/US20150174142A1/en not_active Abandoned
- 2015-06-23 JP JP2015126043A patent/JP6153967B2/ja not_active Expired - Lifetime
-
2016
- 2016-12-13 JP JP2016241318A patent/JP2017048253A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101812160B1 (ko) | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 | |
| USRE43916E1 (en) | Composition for contraception | |
| JP2007512291A (ja) | ２種のエストロゲン及び／又はプロゲスチン組成物を含んで成る、２１〜２８日よりも長い期間にわたっての連続ホルモン処理のための医薬製剤 | |
| ZA200404249B (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| JP4908399B2 (ja) | 天然エストロゲンに基づく段階型避妊製剤 | |
| AU747710B2 (en) | Progestogen-antiprogestogen regimens | |
| US20060079491A1 (en) | Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol | |
| AU2011226911B2 (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
| CN107875388A (zh) | 对延长的激素避孕方案中突破性出血的控制 | |
| HK1246664A1 (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
| HK1186108A (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
| HK1102771A (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20161219 Application number text: 1020157012286 Filing date: 20150511 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170106 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170118 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170726 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20170118 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |